Evidence map›Paper›PMID 32559194›Full record

ArticlePLoS medicine2020

Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts.

Naeimeh Atabaki-Pasdar, Mattias Ohlsson, Ana Viñuela, Francesca Frau, Hugo Pomares-Millan, Mark Haid, Angus G Jones, E Louise Thomas, Robert W Koivula, Azra Kurbasic and 53 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03814915 (DIabetes REsearCh on Patient straTification), which is not on this map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03814915 completednot on this map

DIabetes REsearCh on Patient straTification

TypeobservationalSponsorLund UniversityRan2012 to 2019Enrolled3,049ConditionsType2 Diabetes
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

63 authors at 20 institutions in 11 countries.

Naeimeh Atabaki-PasdarGenetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.ORCID 0000-0001-7229-1888
Mattias OhlssonComputational Biology and Biological Physics Unit, Department of Astronomy and Theoretical Physics, Lund University, Lund, Sweden.ORCID 0000-0003-1145-4297
Ana ViñuelaDepartment of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.ORCID 0000-0003-3771-8537
Francesca FrauSanofi-Aventis Deutschland, Frankfurt am Main, Germany.
Hugo Pomares-MillanGenetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.ORCID 0000-0001-9245-4576
Mark HaidResearch Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum München, Neuherberg, Germany.ORCID 0000-0001-6118-1333
Angus G JonesInstitute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter, Exeter, United Kingdom.ORCID 0000-0002-0883-7599
E Louise ThomasResearch Centre for Optimal Health, School of Life Sciences, University of Westminster, London, United Kingdom.ORCID 0000-0003-4235-4694
Robert W KoivulaGenetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.ORCID 0000-0002-1646-4163
Azra KurbasicGenetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.ORCID 0000-0002-1910-2619
Pascal M MutieGenetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Hugo FitipaldiGenetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.ORCID 0000-0001-5352-2134
Juan FernandezGenetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Adem Y DawedDivision of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom.ORCID 0000-0003-0224-2428
Giuseppe N GiordanoGenetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Ian M ForgieDivision of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom.ORCID 0000-0002-8800-6145
Timothy J McDonaldInstitute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter, Exeter, United Kingdom.
Femke RuttersDepartment of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, the Netherlands.
Henna CederbergDepartment of Endocrinology, Abdominal Centre, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0003-2901-9373
Elizaveta ChabanovaDepartment of Diagnostic Radiology, Copenhagen University Hospital Herlev Gentofte, Herlev, Denmark.
Matilda DaleAffinity Proteomics, Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.ORCID 0000-0002-5788-7744
Federico De MasiDepartment of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0003-4859-4170
Cecilia Engel ThomasAffinity Proteomics, Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.ORCID 0000-0001-6201-6380
Kristine H AllinNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-6880-5759
Tue H HansenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-5948-8993
Alison HeggieInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Mun-Gwan HongAffinity Proteomics, Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.
Petra J M EldersDepartment of General Practice, Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, the Netherlands.ORCID 0000-0002-5907-7219
Gwen KennedyImmunoassay Biomarker Core Laboratory, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom.ORCID 0000-0002-9856-3236
Tarja KokkolaInternal Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0002-3303-3912
Helle Krogh PedersenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-9609-7377
Anubha MahajanWellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-5585-3420
Donna McEvoyInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.ORCID 0000-0003-1546-5567
Francois PattouUniversity of Lille, Inserm, UMR 1190, Translational Research in Diabetes, Department of Endocrine Surgery, CHU Lille, Lille, France.
Violeta RaverdyUniversity of Lille, Inserm, UMR 1190, Translational Research in Diabetes, Department of Endocrine Surgery, CHU Lille, Lille, France.
Ragna S HäusslerAffinity Proteomics, Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.ORCID 0000-0003-1664-8875
Sapna SharmaGerman Center for Diabetes Research, Neuherberg, Germany.
Henrik S ThomsenDepartment of Diagnostic Radiology, Copenhagen University Hospital Herlev Gentofte, Herlev, Denmark.
Jagadish VangipurapuInternal Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0001-6657-2659
Henrik VestergaardNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-3090-269X
Leen M 't HartDepartment of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, the Netherlands.ORCID 0000-0003-4401-2938
Jerzy AdamskiResearch Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum München, Neuherberg, Germany.
Petra B MusholtDiabetes Division, Research and Development, Sanofi, Frankfurt, Germany.
Soren BrageMRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-1265-7355
Søren BrunakDepartment of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
Emmanouil DermitzakisDepartment of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.
Gary FrostSection for Nutrition Research, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.ORCID 0000-0003-0529-6325
Torben HansenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8748-3831
Markku LaaksoInternal Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Oluf PedersenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Martin RidderstråleClinical Pharmacology and Translational Medicine, Novo Nordisk, Søborg, Denmark.
Hartmut RuettenSanofi-Aventis Deutschland, Frankfurt am Main, Germany.
Andrew T HattersleyInstitute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter, Exeter, United Kingdom.ORCID 0000-0001-5620-473X
Mark WalkerInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Joline W J BeulensDepartment of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, the Netherlands.
Andrea MariInstitute of Neuroscience, National Research Council, Padua, Italy.ORCID 0000-0002-1436-5591
Jochen M SchwenkAffinity Proteomics, Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.ORCID 0000-0001-8141-8449
Ramneek GuptaDepartment of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0001-6841-6676
Mark I McCarthyOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-4393-0510
Ewan R PearsonDivision of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom.ORCID 0000-0001-9237-8585
Jimmy D BellResearch Centre for Optimal Health, School of Life Sciences, University of Westminster, London, United Kingdom.ORCID 0000-0003-3804-1281
Imre PavoEli Lilly Regional Operations, Vienna, Austria.
Paul W FranksGenetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.ORCID 0000-0002-0520-7604
Lund University · SEUniversity of Copenhagen · DKScience for Life Laboratory · SEUniversity of Dundee · GBNewcastle University · GBSanofi (Germany) · DEUniversity of Eastern Finland · FIUniversity of Exeter · GBCentre for Human Genetics · GBGentofte Hospital · DKHelmholtz Zentrum München · DEInserm · FRTechnical University of Denmark · DKUniversity of Geneva · CHUniversity of Westminster · GBHarvard University · USHelsinki University Hospital · FIImperial College London · GBLeiden University Medical Center · NLNational Research Council · IT

Funding

Integrating genome-scale data to reveal causal mechanisms in type 2 diabetesU01DK105535 · NIDDK · UNIVERSITY OF OXFORD · PI GLOYN, ANNA LOUISE · 2015 to 2019
$1.7M
Department of Health 17/0005624Medical Research Council MC_UU_00006/4Medical Research Council MC_UU_12015/3NIDDK NIH HHS U01 DK105535Wellcome TrustWellcome Trust 090532Wellcome Trust 098381Wellcome Trust 106130Wellcome Trust 203141Wellcome Trust 212259
6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) is highly prevalent and causes serious health complications in individuals with and without type 2 diabetes (T2D). Early diagnosis of NAFLD is important, as this can help prevent irreversible damage to the liver and, ultimately, hepatocellular carcinomas. We sought to expand etiological understanding and develop a diagnostic tool for NAFLD using machine learning. METHODS AND

findingsWe utilized the baseline data from IMI DIRECT, a multicenter prospective cohort study of 3,029 European-ancestry adults recently diagnosed with T2D (n = 795) or at high risk of developing the disease (n = 2,234). Multi-omics (genetic, transcriptomic, proteomic, and metabolomic) and clinical (liver enzymes and other serological biomarkers, anthropometry, measures of beta-cell function, insulin sensitivity, and lifestyle) data comprised the key input variables. The models were trained on MRI-image-derived liver fat content (<5% or ≥5%) available for 1,514 participants. We applied LASSO (least absolute shrinkage and selection operator) to select features from the different layers of omics data and random forest analysis to develop the models. The prediction models included clinical and omics variables separately or in combination. A model including all omics and clinical variables yielded a cross-validated receiver operating characteristic area under the curve (ROCAUC) of 0.84 (95% CI 0.82, 0.86; p < 0.001), which compared with a ROCAUC of 0.82 (95% CI 0.81, 0.83; p < 0.001) for a model including 9 clinically accessible variables. The IMI DIRECT prediction models outperformed existing noninvasive NAFLD prediction tools. One limitation is that these analyses were performed in adults of European ancestry residing in northern Europe, and it is unknown how well these findings will translate to people of other ancestries and exposed to environmental risk factors that differ from those of the present cohort. Another key limitation of this study is that the prediction was done on a binary outcome of liver fat quantity (<5% or ≥5%) rather than a continuous one.

conclusionsIn this study, we developed several models with different combinations of clinical and omics data and identified biological features that appear to be associated with liver fat accumulation. In general, the clinical variables showed better prediction ability than the complex omics variables. However, the combination of omics and clinical variables yielded the highest accuracy. We have incorporated the developed clinical models into a web interface (see: https://www.predictliverfat.org/) and made it available to the community.

trial registrationClinicalTrials.gov NCT03814915.

Indexed as

Machine LearningDiabetes ComplicationsFatty LiverFemaleHumansMaleMiddle AgedModels, StatisticalProspective StudiesReproducibility of ResultsRisk Assessment

Identifiers

PMID32559194
PMCPMC7304567
OpenAlexW3035784389

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.